



Stanford Cancer Institute

Blood and Marrow Transplant

Version Date: February 29, 2024

Supportive Care BMT364 BMT393 VAR0256 Eligibility: Adult Patients (>= 18 yo) Receiving Human Leukocyte Antigen (HLA) Matched Phase TBD Viral Phase III Phase TBD Allogeneic Peripheral BMT Randomized Aromatherapy Specific Placebo-Inhaler Use for T-Lymphocytes by Cytokine Capture Controlled Study Hematopoietic to Examine the Stem Cell System (CCS) to Efficacy & Safety Transplant Patient Treat Infection w/ HEM0064 of DAS181 for the Distress Adenovirus Phase III Treatment of Cytomegalovirus Multicenter PI: Florom-Smith or Epstein-Barr Lower Respiratory Randomized Tract Sponsor: Stanford Virus After HCT or Double-Blind Parainfluenza Solid Organ University Study of the Transplantation & Infection in Efficacy and Immunoin Patients w/ Safety of compromised Compromised Rezafungin for Subjects Immunity Injection Versus Standard PI: Brown PI: Alexander Antimicrobial Sponsor: Stanford Sponsor: Ansun Regimen to Biopharma Inc. University Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT Study)



PI: Epstein Sponsor: Cidara Therapeutics, Inc.